Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B

IONIS PHARMACEUTICALS INC

2026-Q1 EPS reported -$0.56 revenue$246,091,000

Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.
TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.
2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).
Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.
Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.